Heart and Vessels

, Volume 29, Issue 3, pp 287–299 | Cite as

Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials

  • Hisato Takagi
  • Masao Niwa
  • Yusuke Mizuno
  • Hirotaka Yamamoto
  • Shin-nosuke Goto
  • Takuya Umemoto
Original Article

Abstract

In addition to their high-intensity effects on the reduction in low-density lipoprotein (LDL) levels, rosuvastatin and atorvastatin would be expected to also reduce small dense LDL (sdLDL) levels. To determine which reduces sdLDL levels more, we performed the first meta-analysis and meta-regression of randomized head-to-head trials of rosuvastatin versus atorvastatin therapy. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through April 2012. Eligible studies were prospective, randomized controlled trials of rosuvastatin versus atorvastatin therapy reporting final sdLDL (directly measured or calculated) levels as an outcome. For each study, data regarding final sdLDL levels in both the rosuvastatin and atorvastatin groups were used to generate mean differences (MD) and 95 % confidence intervals (CI). Meta-regression analysis was performed to determine whether the effects of rosuvastatin therapy were modulated by the prespecified factors. Of 159 potentially relevant articles screened initially, 28 reports of randomized trials enrolling a total of 7802 patients were included. Pooled analysis suggested a significant reduction in final sdLDL levels among patients randomized to rosuvastatin versus atorvastatin therapy (MD, −1.56 mg/dl; 95 % CI, −2.30 to −0.83 mg/dl; P < 0.0001). The meta-regression coefficients were statistically significant for the baseline LDL/sdLDL level and the difference in LDL changes between the two groups. In conclusion, rosuvastatin rather than atorvastatin therapy is likely more effective in reduction of sdLDL levels. It should be further investigated whether the reduction in sdLDL levels implies overt clinical benefits of rosuvastatin over atorvastatin.

Keywords

Atorvastatin Meta-analysis Randomized trial Rosuvastatin Small dense low-density lipoprotein 

Notes

Conflict of interest

No author has any conflict of interest associated with this article.

Supplementary material

380_2013_358_MOESM1_ESM.pdf (837 kb)
Supplementary material 1 (PDF 836 kb)

References

  1. 1.
    Krauss RM, Blanche PJ (1992) Detection and quantitation of LDL subfractions. Curr Opin Lipidol 3:377–383CrossRefGoogle Scholar
  2. 2.
    Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7:53–72PubMedCrossRefGoogle Scholar
  3. 3.
    Packard CJ (2006) Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17:412–417PubMedCrossRefGoogle Scholar
  4. 4.
    St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP, Lamarche B (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25:553–559PubMedCrossRefGoogle Scholar
  5. 5.
    Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ (2006) Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113:20–29PubMedCrossRefGoogle Scholar
  6. 6.
    Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM (1996) Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94:2146–2153PubMedCrossRefGoogle Scholar
  7. 7.
    Zambon A, Hokanson JE, Brown BG, Brunzell JD (1999) Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959–1964PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenson RS, Otvos JD, Freedman DS (2002) Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90:89–94PubMedCrossRefGoogle Scholar
  9. 9.
    Rizzo M, Berneis K (2007) Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract 61:1949–1956PubMedCrossRefGoogle Scholar
  10. 10.
    Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J (1990) Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83:59–67PubMedCrossRefGoogle Scholar
  11. 11.
    Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN (2002) Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta 317:119–123PubMedCrossRefGoogle Scholar
  12. 12.
    Hoefner DM, Hodel SD, O’Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47:266–274PubMedGoogle Scholar
  13. 13.
    Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R (2002) Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22:1175–1180PubMedCrossRefGoogle Scholar
  14. 14.
    Ito Y, Fujimura M, Ohta M, Hirano T (2011) Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 57:57–65PubMedCrossRefGoogle Scholar
  15. 15.
    Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll MH (2011) Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am J Clin Pathol 36:20–29CrossRefGoogle Scholar
  16. 16.
    Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, Barnes BO, Cox WR, Zieve FJ, Isaacsohn J, Ycas J, Sager PT, Gold A, ARIES Study Group (2006) Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 97:229–235PubMedCrossRefGoogle Scholar
  17. 17.
    Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group (2007) Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 99:1538–1543PubMedCrossRefGoogle Scholar
  18. 18.
    Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRefGoogle Scholar
  19. 19.
    Higgins JP, Deeks JJ, Altman DG (eds) (2011) Chapter 16: Special topics in statistics. In: Higgins JP, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Assessed 1 May 2012
  20. 20.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMedGoogle Scholar
  21. 21.
    Bahadir MA, Oguz A, Uzunlulu M, Bahadir O (2009) Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 16:684–690PubMedCrossRefGoogle Scholar
  22. 22.
    Mori Y, Kuriyama G, Tanaka T, Tajima N (2009) Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 36:412–418PubMedCrossRefGoogle Scholar
  23. 23.
    Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ (2008) Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101:315–318PubMedCrossRefGoogle Scholar
  24. 24.
    Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M (2011) Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J Clin Pract 65:679–683PubMedCrossRefGoogle Scholar
  25. 25.
    Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Park SW, Park SJ (2012) Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP Trial). Am J Cardiol 109:1700–1704PubMedCrossRefGoogle Scholar
  26. 26.
    Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, Goudevenos J, Mikhailidis DP, Elisaf MS (2006) Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 22:1123–1131PubMedCrossRefGoogle Scholar
  27. 27.
    Brunetti ND, Maulucci G, Casavecchia GP, Distaso C, De Gennaro L, Pellegrino PL, Di Biase M, Brunetti ND, Maulucci G, Casavecchia GP, Distaso C, De Gennaro L, Pellegrino PL, Di Biase M (2007) Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. J Interv Cardiol 20:481–487PubMedCrossRefGoogle Scholar
  28. 28.
    Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H (2002) Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89:268–275PubMedCrossRefGoogle Scholar
  29. 29.
    Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F, ECLIPSE Study Investigators (2008) Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 111:219–228PubMedCrossRefGoogle Scholar
  30. 30.
    Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, Manabe I, Lee SH (2010) Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 15:167–174PubMedCrossRefGoogle Scholar
  31. 31.
    Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC (2011) Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 75:398–406PubMedCrossRefGoogle Scholar
  32. 32.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study (2010) Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 64:1052–1061PubMedCrossRefGoogle Scholar
  33. 33.
    Liu B, Cao HM, Li GY, Liu M, Feng J, Li J, Wang Q (2011) Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. J Int Med Res 39:2314–2322PubMedCrossRefGoogle Scholar
  34. 34.
    Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A (2008) Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs 8:265–270PubMedCrossRefGoogle Scholar
  35. 35.
    Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group (2004) Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 147:705–713PubMedCrossRefGoogle Scholar
  36. 36.
    Okada K, Kimura K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, Shimizu M, Iwasawa Y, Morita Y, Wada A, Shigemasa T, Mochida Y, Shimizu T, Sawada R, Uchino K, Umemura S (2011) Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. From the viewpoint of cholesterol metabolism. Circ J 75:2496–2504PubMedCrossRefGoogle Scholar
  37. 37.
    Olsson AG, Pears J, McKellar J, Mizan J, Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504–508PubMedCrossRefGoogle Scholar
  38. 38.
    Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group (2002) Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 144:1044–1051PubMedCrossRefGoogle Scholar
  39. 39.
    Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F, POLARIS study investigators (2007) Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 194:e154–e164PubMedCrossRefGoogle Scholar
  40. 40.
    Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, Ferrante E, Ciabattoni G, Scarpini F, Ghezzi A, Auteri A, Davì G (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214:122–128PubMedCrossRefGoogle Scholar
  41. 41.
    Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH (2005) LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and atorvastatin in different dosages and reverse cholesterol transport) study. Curr Med Res Opin 21:1865–1874PubMedCrossRefGoogle Scholar
  42. 42.
    Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK (2009) Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in Caucasian men with a previous atherosclerotic event. Am J Cardiol 103:437–441PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087PubMedCrossRefGoogle Scholar
  44. 44.
    Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG (2003) Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 91:33–41PubMedCrossRefGoogle Scholar
  45. 45.
    Sindhu S, Singh HK, Salman MT, Fatima J, Verma VK (2011) Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. J Pharmacol Pharmacother 2:261–265PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Kurabayashi M, Yamazaki T, SUBARU Study Group (2008) Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study-more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 15:314–323PubMedCrossRefGoogle Scholar
  47. 47.
    Tsutamoto T, Sakai H, Ibe K, Yamaji M, Kawahara C, Nakae I, Fujii M, Yamamoto T, Horie M (2011) Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 75:2160–2166PubMedCrossRefGoogle Scholar
  48. 48.
    Weng TC, Yang YH, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35:139–151PubMedCrossRefGoogle Scholar
  49. 49.
    Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105:69–76PubMedCrossRefGoogle Scholar
  50. 50.
    Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 51:1546–1553PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ (2010) Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 56:967–976PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, Katagiri T (2008) Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 15:250–260PubMedCrossRefGoogle Scholar
  53. 53.
    Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, Rhee J, Lee SJ, Park JK, Lim JY, Yoon YW, Hong BK (2006) Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 47:405–414PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Rizzo M, Pernice V, Frasheri A, Di Lorenzo G, Rini GB, Spinas GA, Berneis K (2009) Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 70:870–875CrossRefGoogle Scholar
  55. 55.
    Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152–160PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Hisato Takagi
    • 1
  • Masao Niwa
    • 1
  • Yusuke Mizuno
    • 1
  • Hirotaka Yamamoto
    • 1
  • Shin-nosuke Goto
    • 1
  • Takuya Umemoto
    • 1
  1. 1.Department of Cardiovascular SurgeryShizuoka Medical CenterShizuokaJapan

Personalised recommendations